X-linked hypophosphatemia
Jump to navigation
Jump to search
Epidemiology
- bony abnormalities are less common in women
Pathology
- reduced proximal tubular resorption of phosphate
- increased fractional excretion of phosphate
- osteomalacia develops in adult life
- overgrowth of bones at sites of muscular tendon attachment may compress nerves or limit movement
- increased secretion of FGF-23
Genetics
Clinical manifestations
- patients may be asymptomatic
- short stature, rachitic bones
- recurrent striss fractures
- dental abscesses
- legs are particularly short & deformed
- bone age & dentition are retarded
- skull becomes deformed
- maxillofacial region may be abnormal
Laboratory
- serum chemistries
- serum phosphorus: hypophosphatemia
- alkaline phosphatase in serum is elevated
- serum parathyroid hormone (PTH) is normal or high
- serum calcium is normal
- urine chemistries
- urine calcium: Ca+2 excretion is normal or low
- glycine in urine: mild glycinuria
- glucose in urine: glycosuria may occur
Management
- phosphate (NutraPhos) 1-4 g/day in divided doses
- calcitriol or some other form of vitamin D
- burosumab improves renal tubular phosphate reabsorption, serum phosphorus levels, linear growth, & physical function & reduces pain & severity of rickets[2]
- orthopedic management
- delay corrective surgery until active growth phase is complete (exception is genu valgum {knock knee})
More general terms
References
- ↑ Harrison's Principles of Internal Medicine, 13th ed. Isselbacher et al (eds), McGraw-Hill Inc. NY, 1994, pg 1328
- ↑ 2.0 2.1 Carpenter TO, Whyte MP, Imel EA Burosumab Therapy in Children with X-Linked Hypophosphatemia. N Engl J Med 2018; 378:1987-1998. May 24, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29791829 https://www.nejm.org/doi/full/10.1056/NEJMoa1714641